Medtronic (Minneapolis) reported the initiation of a randomized clinical trial in Europe to assess the benefits of ablation using the Medtronic Arctic Front Advance cryoballoon as a first-line treatment for atrial fibrillation patients. While medication is currently considered first-line treatment for AF, research indicates that half of all patients with symptomatic disease do not respond to drug therapy, the company noted, adding that earlier ablation may improve treatment effectiveness.
Read More
